NO20021329L - Kinaseinhibitorer som terapeutiske midler - Google Patents

Kinaseinhibitorer som terapeutiske midler

Info

Publication number: NO20021329L
Authority: NO; Norway
Prior art keywords: therapeutic agents; kinase inhibitors; kinase; inhibitors; therapeutic
Prior art date: 1999-09-17

Application number

NO20021329A

Other languages

English (en)

Other versions

NO20021329D0 (no

Inventor

Gavin C Hirst

Paul Rafferty

David Calderwood

Helen Louise Twigger

Stephen St Gallay

Kurt Ritter

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-17

Filing date

2002-03-18

Publication date

2002-05-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22552056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021329(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-18 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2002-03-18 Publication of NO20021329D0 publication Critical patent/NO20021329D0/no

2002-05-21 Publication of NO20021329L publication Critical patent/NO20021329L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Oncology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20021329A 1999-09-17 2002-03-18 Kinaseinhibitorer som terapeutiske midler NO20021329L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15461899P	1999-09-17	1999-09-17
PCT/US2000/025357 WO2001019828A2 (en)	1999-09-17	2000-09-15	Kinase inhibitors as therapeutic agents

Publications (2)

Publication Number	Publication Date
NO20021329D0 NO20021329D0 (no)	2002-03-18
NO20021329L true NO20021329L (no)	2002-05-21

Family

ID=22552056

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021329A NO20021329L (no)	1999-09-17	2002-03-18	Kinaseinhibitorer som terapeutiske midler

Country Status (27)

Country	Link
EP (1)	EP1268481B1 (no)
JP (1)	JP2003509427A (no)
KR (1)	KR20020063854A (no)
CN (1)	CN1390220A (no)
AR (1)	AR029766A1 (no)
AT (1)	ATE380814T1 (no)
AU (1)	AU7491400A (no)
BG (1)	BG106585A (no)
BR (1)	BR0014075A (no)
CA (1)	CA2385769A1 (no)
CY (1)	CY1107886T1 (no)
CZ (1)	CZ2002934A3 (no)
DE (1)	DE60037455T2 (no)
DK (1)	DK1268481T3 (no)
ES (1)	ES2299434T3 (no)
HK (1)	HK1053831A1 (no)
HU (1)	HUP0303363A2 (no)
IL (1)	IL148719A0 (no)
MX (1)	MXPA02002938A (no)
NO (1)	NO20021329L (no)
NZ (1)	NZ517759A (no)
PL (1)	PL354241A1 (no)
PT (1)	PT1268481E (no)
SK (1)	SK3792002A3 (no)
TR (1)	TR200201506T2 (no)
WO (1)	WO2001019828A2 (no)
ZA (1)	ZA200202122B (no)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en)	2000-10-23	2005-12-22	Smithkline Beecham Corporation	Novel compounds
US7427623B2 (en)	2001-09-11	2008-09-23	Smithkline Beecham Corporation	4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
JPWO2003070730A1 (ja) *	2002-02-22	2005-06-09	帝人株式会社	ピロロピリミジン誘導体
US20030225273A1 (en) *	2002-03-21	2003-12-04	Michaelides Michael R.	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7560552B2 (en)	2002-03-21	2009-07-14	Abbott Laboratories	Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
ATE370952T1 (de)	2002-04-19	2007-09-15	Smithkline Beecham Corp	Neue verbindungen
US7427616B2 (en)	2002-08-06	2008-09-23	Astrazeneca Ab	Condensed pyridines and pyrimidines with tie2 (TEK) activity
EP1620094A4 (en) *	2003-05-06	2010-04-28	Glaxosmithkline Llc	NEW CHEMICAL COMPOUNDS
US7297709B2 (en)	2003-05-22	2007-11-20	Abbott Laboratories	Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7129260B2 (en)	2003-06-02	2006-10-31	Abbott Laboratories	Isoindolinone kinase inhibitors
US20050026944A1 (en) *	2003-07-24	2005-02-03	Patrick Betschmann	Thienopyridine and furopyridine kinase inhibitors
US7202363B2 (en)	2003-07-24	2007-04-10	Abbott Laboratories	Thienopyridine and furopyridine kinase inhibitors
AU2004260689B8 (en) *	2003-07-29	2008-05-15	Irm Llc	Compounds and compositions as protein kinase inhibitors
DE602004025504D1 (de) *	2003-12-23	2010-03-25	Novartis Ag	Bicyclische heterocyclische p-38-kinase-inhibitoren
TW200530236A (en) *	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
WO2005111001A1 (en) *	2004-05-19	2005-11-24	Astrazeneca Ab	Novel fused heterocycles and uses thereof
FR2871158A1 (fr)	2004-06-04	2005-12-09	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US20070054916A1 (en) *	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
ES2386027T3 (es)	2004-10-29	2012-08-07	Abbott Laboratories	Inhibidores de quinasas novedosos
DE102004061288A1 (de) *	2004-12-14	2006-06-29	Schering Ag	3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
PE20061119A1 (es)	2005-01-19	2006-11-27	Aventis Pharma Sa	PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP1683796A1 (en) *	2005-01-24	2006-07-26	Schering Aktiengesellschaft	Pyrazolopyridines, their preparation and their medical use
US7842809B2 (en)	2005-01-24	2010-11-30	Bayer Schering Pharma Ag	Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
US20100047338A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP2008535822A (ja)	2005-03-25	2008-09-04	グラクソグループリミテッド	新規化合物
WO2006104917A2 (en)	2005-03-25	2006-10-05	Glaxo Group Limited	Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
TW200724142A (en)	2005-03-25	2007-07-01	Glaxo Group Ltd	Novel compounds
AR053346A1 (es)	2005-03-25	2007-05-02	Glaxo Group Ltd	Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
US7884109B2 (en)	2005-04-05	2011-02-08	Wyeth Llc	Purine and imidazopyridine derivatives for immunosuppression
US7795248B2 (en)	2005-05-18	2010-09-14	Abbott Laboratories, Inc.	Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
FR2889526B1 (fr)	2005-08-04	2012-02-17	Aventis Pharma Sa	7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
TW200800983A (en) *	2005-09-14	2008-01-01	Janssen Pharmaceutica Nv	5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CN101305000A (zh) *	2005-09-14	2008-11-12	詹森药业有限公司	作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类
EP2325186B1 (en)	2005-11-17	2014-10-08	OSI Pharmaceuticals, LLC	Fused Bicyclic mTor Inhibitors
PE20070855A1 (es) *	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US8143393B2 (en) *	2005-12-02	2012-03-27	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738725A (en) *	2006-01-25	2007-10-16	Osi Pharm Inc	Unsaturated mTOR inhibitors
ATE479434T1 (de) *	2006-02-14	2010-09-15	Vertex Pharma	Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
US7989459B2 (en)	2006-02-17	2011-08-02	Pharmacopeia, Llc	Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20100234351A1 (en) *	2006-02-23	2010-09-16	Takeda Pharmaceutical Company Limited	Fused nitrogen-comprising heterocyclic compound
TW200815437A (en) *	2006-06-13	2008-04-01	Bayer Schering Pharma Ag	Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008022060A2 (en) *	2006-08-14	2008-02-21	Novartis Ag	Imidazo-pyridine derivatives for modulating protein kinase activity
US7897762B2 (en) *	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
WO2008043019A1 (en)	2006-10-04	2008-04-10	Pharmacopeia, Inc	8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
WO2008043031A1 (en)	2006-10-04	2008-04-10	Pharmacopeia, Inc.	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en)	2006-10-04	2011-03-08	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
KR101157848B1 (ko) *	2007-03-22	2012-07-11	다케다 야쿠힌 고교 가부시키가이샤	Ｐｌｋ１ 저해제로서 유용한 치환된 피리미도디아제핀
CN101679412A (zh)	2007-05-23	2010-03-24	药典有限责任公司	作为PKC-θ抑制剂的嘌呤酮类和1H-咪唑并吡啶酮类
DE102007024470A1 (de)	2007-05-24	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2564850B1 (en)	2007-09-25	2014-08-13	Takeda Pharmaceutical Company Limited	Polo-like kinase inhibitors
EP2072502A1 (de)	2007-12-20	2009-06-24	Bayer Schering Pharma Aktiengesellschaft	Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
CN101239978A (zh) *	2008-03-05	2008-08-13	南方医科大学	一种咪唑并吡啶类化合物
CA2719134C (en)	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
EP2303889A1 (en)	2008-06-18	2011-04-06	F. Hoffmann-La Roche AG	Halo-substituted pyrimidodiazepines as plkl inhibitors
EP2373662B1 (en)	2008-12-05	2014-09-24	AbbVie Bahamas Ltd.	Thieno[3,2-c]pyridine derivatives as kinase inhibitors for use in the treatment of cancer
US20110312916A1 (en)	2009-02-05	2011-12-22	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US8846673B2 (en)	2009-08-11	2014-09-30	Bristol-Myers Squibb Company	Azaindazoles as kinase inhibitors and use thereof
KR20120094920A (ko)	2009-09-25	2012-08-27	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
CA2773827A1 (en)	2009-09-25	2011-03-31	Vertex Pharmaceuticals Incorporated	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
RU2560162C2 (ru)	2010-02-08	2015-08-20	Мерк Шарп и Доум Б.В.	СОЕДИНЕНИЯ 8-МЕТИЛ-1-ФЕНИЛИМИДАЗО[1, 5-а]ПИРАЗИНА
AU2015202128B2 (en) *	2010-05-31	2015-05-28	Ono Pharmaceutical Co., Ltd.	Purinone derivative
JP5648686B2 (ja)	2010-05-31	2015-01-07	小野薬品工業株式会社	プリノン誘導体
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
ES2950569T3 (es)	2011-07-19	2023-10-11	Merck Sharp & Dohme	(S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk
US8436179B2 (en)	2011-07-20	2013-05-07	Abbvie Inc.	Kinase inhibitor with improved solubility profile
HUE031094T2 (en) *	2011-11-29	2017-07-28	Ono Pharmaceutical Co	Purinone derivative hydrochloride
JP6047582B2 (ja)	2011-12-15	2016-12-21	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	置換ベンゾチエニル−ピロロトリアジンおよび癌の処置におけるその使用
UY34484A (es)	2011-12-15	2013-07-31	Bayer Ip Gmbh	Benzotienilo-pirrolotriazinas disustituidas y sus usos
US8501724B1 (en) *	2012-01-31	2013-08-06	Pharmacyclics, Inc.	Purinone compounds as kinase inhibitors
US9475815B2 (en)	2012-02-23	2016-10-25	Bayer Intelletual Property Gmbh	Substituted benzothienyl-pyrrolotriazines and uses thereof
KR20190043648A (ko)	2012-05-31	2019-04-26	파마사이언스 인크.	단백질 키나제 저해제
CA2782774A1 (en)	2012-07-06	2014-01-06	Pharmascience Inc.	Protein kinase inhibitors
CN105796569A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
CN105796562A (zh) *	2012-09-10	2016-07-27	杨子娇	化合物在制备防治青光眼病的药物中的用途
WO2014113942A1 (en)	2013-01-23	2014-07-31	Merck Sharp & Dohme Corp.	Btk inhibitors
US9481682B2 (en)	2013-01-23	2016-11-01	Merck Sharp & Dohme Corp.	Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
BR112015023098A2 (pt)	2013-03-14	2017-07-18	Univ Jefferson	agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
WO2015002894A1 (en) *	2013-07-02	2015-01-08	Pharmacyclics, Inc.	Purinone compounds as kinase inhibitors
US9808472B2 (en)	2013-08-12	2017-11-07	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CA2833701A1 (en) *	2013-11-19	2015-05-19	Pharmascience Inc.	Protein kinase inhibitors
CA2833867A1 (en) *	2013-11-21	2015-05-21	Pharmascience Inc.	Protein kinase inhibitors
US10328080B2 (en)	2013-12-05	2019-06-25	Acerta Pharma, B.V.	Therapeutic combination of PI3K inhibitor and a BTK inhibitor
WO2015095102A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Btk inhibitors
EP3082809B1 (en)	2013-12-20	2021-01-20	Merck Sharp & Dohme Corp.	Btk inhibitors
EP3094314B1 (en)	2014-01-16	2021-06-23	MUSC Foundation For Research Development	Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en)	2014-01-21	2019-04-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
EP3122360B1 (en)	2014-03-25	2020-06-17	ONO Pharmaceutical Co., Ltd.	Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
WO2015181633A2 (en)	2014-04-11	2015-12-03	Acerta Pharma B.V.	Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US9949971B2 (en)	2014-06-17	2018-04-24	Acerta Pharma B.V.	Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
TW201618772A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
WO2016106626A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106628A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Btk inhibitors
WO2016106629A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Btk inhibitors
WO2016106623A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Benzamide imidazopyrazine btk inhibitors
WO2016106624A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Tertiary alcohol imidazopyrazine btk inhibitors
US10239879B2 (en)	2015-04-09	2019-03-26	Ono Pharmaceutical Co., Ltd.	Process for producing purinone derivative
DK3317281T3 (da)	2015-07-02	2020-06-15	Acerta Pharma Bv	Faste former og formuleringer af (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamid
CN105130932B (zh) *	2015-07-14	2017-06-16	中国科学院微生物研究所	化合物及其在制备ptp1b抑制剂和治疗和/或预防ⅱ型糖尿病的药物的用途
US10053465B2 (en)	2015-08-26	2018-08-21	Incyte Corporation	Pyrrolopyrimidine derivatives as TAM inhibitors
HRP20231614T1 (hr)	2016-03-28	2024-03-15	Incyte Corporation	Spojevi pirolotriazina kao tam inhibitori
US20180072741A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyrimidine compounds and uses thereof
MA46191A (fr)	2016-09-09	2021-04-21	Incyte Corp	Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US10280164B2 (en)	2016-09-09	2019-05-07	Incyte Corporation	Pyrazolopyridone compounds and uses thereof
US20180228786A1 (en)	2017-02-15	2018-08-16	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en)	2017-09-08	2019-03-14	Incyte Corporation	6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
EP3988552A1 (en)	2017-09-27	2022-04-27	Incyte Corporation	Salts of pyrrolotriazine derivatives useful as tam inhibitors
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
WO2019164847A1 (en)	2018-02-20	2019-08-29	Incyte Corporation	Indazole compounds and uses thereof
KR20200133747A (ko)	2018-02-20	2020-11-30	인사이트 코포레이션	암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
PE20211805A1 (es)	2018-06-29	2021-09-14	Incyte Corp	Formulaciones de un inhibidor de axl/mer
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
MA53726A (fr)	2018-09-25	2022-05-11	Incyte Corp	Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
JP2022543155A (ja)	2019-08-06	2022-10-07	インサイト・コーポレイション	Ｈｐｋ１阻害剤の固体形態
AU2021230385A1 (en)	2020-03-06	2022-09-22	Incyte Corporation	Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
WO2024240088A1 (en) *	2023-05-19	2024-11-28	Chengdu Anticancer Bioscience , Ltd.	Compounds, compositions and methods of treating disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TR199902301T2 (xx) *	1997-03-19	1999-12-21	Basf Aktiengesellschaft	Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents

2000
- 2000-09-15 SK SK379-2002A patent/SK3792002A3/sk unknown
- 2000-09-15 CZ CZ2002934A patent/CZ2002934A3/cs unknown
- 2000-09-15 KR KR1020027003507A patent/KR20020063854A/ko not_active Application Discontinuation
- 2000-09-15 NZ NZ517759A patent/NZ517759A/en unknown
- 2000-09-15 IL IL14871900A patent/IL148719A0/xx unknown
- 2000-09-15 MX MXPA02002938A patent/MXPA02002938A/es unknown
- 2000-09-15 DE DE60037455T patent/DE60037455T2/de not_active Expired - Lifetime
- 2000-09-15 DK DK00963510T patent/DK1268481T3/da active
- 2000-09-15 PT PT00963510T patent/PT1268481E/pt unknown
- 2000-09-15 JP JP2001523405A patent/JP2003509427A/ja not_active Withdrawn
- 2000-09-15 ES ES00963510T patent/ES2299434T3/es not_active Expired - Lifetime
- 2000-09-15 AT AT00963510T patent/ATE380814T1/de active
- 2000-09-15 CN CN00815776A patent/CN1390220A/zh active Pending
- 2000-09-15 CA CA002385769A patent/CA2385769A1/en not_active Abandoned
- 2000-09-15 TR TR2002/01506T patent/TR200201506T2/xx unknown
- 2000-09-15 WO PCT/US2000/025357 patent/WO2001019828A2/en active IP Right Grant
- 2000-09-15 BR BR0014075-9A patent/BR0014075A/pt not_active IP Right Cessation
- 2000-09-15 PL PL00354241A patent/PL354241A1/xx not_active Application Discontinuation
- 2000-09-15 EP EP00963510A patent/EP1268481B1/en not_active Expired - Lifetime
- 2000-09-15 AU AU74914/00A patent/AU7491400A/en not_active Abandoned
- 2000-09-15 HU HU0303363A patent/HUP0303363A2/hu unknown
- 2000-09-18 AR ARP000104887A patent/AR029766A1/es unknown
2002
- 2002-03-14 ZA ZA200202122A patent/ZA200202122B/en unknown
- 2002-03-18 NO NO20021329A patent/NO20021329L/no not_active Application Discontinuation
- 2002-04-05 BG BG106585A patent/BG106585A/xx unknown
2003
- 2003-06-19 HK HK03104425.4A patent/HK1053831A1/zh unknown
2008
- 2008-02-14 CY CY20081100173T patent/CY1107886T1/el unknown

Also Published As

Publication number	Publication date
NZ517759A (en)	2004-04-30
JP2003509427A (ja)	2003-03-11
DE60037455T2 (de)	2008-11-27
MXPA02002938A (es)	2004-12-06
DK1268481T3 (da)	2008-05-05
DE60037455D1 (de)	2008-01-24
BG106585A (en)	2003-03-31
SK3792002A3 (en)	2003-09-11
BR0014075A (pt)	2002-07-16
HK1053831A1 (zh)	2003-11-07
CA2385769A1 (en)	2001-03-22
CY1107886T1 (el)	2013-06-19
PT1268481E (pt)	2008-03-19
AU7491400A (en)	2001-04-17
ZA200202122B (en)	2003-08-27
EP1268481B1 (en)	2007-12-12
PL354241A1 (en)	2003-12-29
EP1268481A2 (en)	2003-01-02
ATE380814T1 (de)	2007-12-15
HUP0303363A2 (hu)	2004-07-28
TR200201506T2 (tr)	2002-10-21
ES2299434T3 (es)	2008-06-01
KR20020063854A (ko)	2002-08-05
WO2001019828A3 (en)	2001-10-04
IL148719A0 (en)	2002-09-12
NO20021329D0 (no)	2002-03-18
WO2001019828A2 (en)	2001-03-22
AR029766A1 (es)	2003-07-16
CN1390220A (zh)	2003-01-08
CZ2002934A3 (cs)	2002-07-17

Publication	Publication Date	Title
NO20021329D0 (no)	2002-03-18	Kinaseinhibitorer som terapeutiske midler
NO20021239D0 (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
PT1226136E (pt)	2005-04-29	Inibidores da tirosina quinase
DK1212327T3 (da)	2003-12-15	Pyrazolopyrimidiner som terapeutiske midler
NO20023828L (no)	2002-09-30	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
DK1140840T3 (da)	2006-07-31	omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
ATE318603T1 (de)	2006-03-15	Pyrrolotriazin kinasehemmer
NO20015065L (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
EP1296697A4 (en)	2005-02-16	Therapeutic agents - i
NO20031006L (no)	2003-03-04	Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
NO20021400D0 (no)	2002-03-20	Terapeutiske konazolinderivater
NO20034176L (no)	2003-11-21	Pyrazolopyrimidiner som terapeutiske midler
NO20034177L (no)	2003-11-21	Pyrazolopyrimidiner som terapeutiske midler
DK1337527T3 (da)	2010-01-04	Indolylmaleinimidderivater som proteinkinase C-inhibitorer
DE60002193D1 (de)	2003-05-22	Metalloprotease inhibitoren
ID30460A (id)	2001-12-06	Inhibitor-inhibitor protein siklik tirosin kinase
PT1235558E (pt)	2006-09-29	Agentes terapeuticos
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
NO20014243L (no)	2001-10-17	Dihetero-substituerte metalloproteaseinhibitorer
NO20021959L (no)	2002-05-29	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20016301D0 (no)	2001-12-21	Terapeutiske midler
DK1690853T3 (da)	2010-06-07	Omega-carboxyaryl-substituerede diphenylurinstoffer til anvendelse som raf-kinaseinhibitorer
SI1268481T1 (sl)	2008-06-30	Inhibitorji kinaze kot zdravila
IDP000027420A (id)	2001-12-20	Inhibitor-inhibitor kinase pirolotriazin

Legal Events

Date	Code	Title	Description
2005-01-17	FC2A	Withdrawal, rejection or dismissal of laid open patent application